Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers

Cell Rep Med. 2023 Mar 21;4(3):100977. doi: 10.1016/j.xcrm.2023.100977. Epub 2023 Mar 14.

Abstract

Although breast cancer mortality is largely caused by metastasis, clinical decisions are based on analysis of the primary tumor and on lymph node involvement but not on the phenotype of disseminated cells. Here, we use multiplex imaging mass cytometry to compare single-cell phenotypes of primary breast tumors and matched lymph node metastases in 205 patients. We observe extensive phenotypic variability between primary and metastatic sites and that disseminated cell phenotypes frequently deviate from the clinical disease subtype. We identify single-cell phenotypes and spatial organizations of disseminated tumor cells that are associated with patient survival and a weaker survival association for high-risk phenotypes in the primary tumor. We show that p53 and GATA3 in lymph node metastases provide prognostic information beyond clinical classifiers and can be measured with standard methods. Molecular characterization of disseminated tumor cells is an untapped source of clinically applicable prognostic information for breast cancer.

Keywords: breast cancer; disseminating tumor cells; imaging mass cytometry; lymph node metastases; metastasis; metastatic process; multiplexed imaging; prognostics signature; single-cell analysis; survival analysis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Lymph Nodes* / diagnostic imaging
  • Lymph Nodes* / pathology
  • Lymphatic Metastasis / pathology
  • Prognosis